©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Adenovirus-mediated Overexpression of Liver 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase in Gluconeogenic Rat Hepatoma Cells
PARADOXICAL EFFECT ON Fru-2,6-P(2) LEVELS (*)

(Received for publication, June 5, 1995; and in revised form, July 24, 1995)

Doriane Argaud (3)(§) Alex J. Lange (3) Thomas C. Becker (2) David A. Okar (3) M. Raafat El-Maghrabi (1) Christopher B. Newgard (2) Simon J. Pilkis (3)(¶)

From the  (1)From theDepartment of Physiology and Biophysics, Health Science Center, SUNY at Stony Brook, Stony Brook, New York 11794, the (2)Department of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235-7200, and the (3)Department of Biochemistry, University of Minnesota, Minneapolis, Minnesota 55455-0347

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase has been postulated to be a metabolic signaling enzyme, which acts as a switch between glycolysis and gluconeogenesis in mammalian liver by regulating the level of fructose 2,6-bisphosphate. The effect of overexpressing the bifunctional enzyme was studied in FAO cells transduced with recombinant adenoviral constructs of either the wild-type enzyme or a double mutant that has no bisphosphatase activity or protein kinase phosphorylation site. With both constructs, the mRNA and protein were overexpressed by 150- and 40-fold, respectively. Addition of cAMP to cells overexpressing the wild-type enzyme increased the S(0.5) for fructose 6-phosphate of the kinase by 1.5-fold but had no effect on the overexpressed double mutant. When the wild-type enzyme was overexpressed, there was a decrease in fructose 2,6-bisphosphate levels, even though 6-phosphofructo-2-kinase maximal activity increased more than 22-fold and was in excess of fructose-2,6-bisphosphatase maximal activity. The kinase:bisphosphatase maximal activity ratio was decreased, indicating that the overexpressed enzyme was phosphorylated by cAMP-dependent protein kinase. Overexpression of the double mutant resulted in a 28-fold increase in kinase maximal activity and a 3-4-fold increase in fructose 2,6-bisphosphate levels. Overexpression of this form inhibited the rate of glucose production from dihydroxyacetone by 90% and stimulated the rate of lactate plus pyruvate production by 200%. In contrast, overexpression of the wild-type enzyme enhanced glucose production and inhibited lactate plus pyruvate production. These results provide direct support for fructose 2,6-bisphosphate as a regulator of gluconeogenic/glycolytic pathway flux and suggest that regulation of bifunctional enzyme activities by covalent modification is more important than the amount of the protein.


INTRODUCTION

Gluconeogenic/glycolytic pathway flux is regulated by allosteric effectors and by covalent modification of key regulatory enzymes and/or by modulation of gene expression of these enzymes(1, 2) . Until recently, it has not been possible to alter properties of an enzyme in a metabolic pathway in a systematic manner and then test the effect on the function of the entire pathway in an intact cell. The development of host/vector systems containing powerful promoters has allowed transfer and expression of normal and mutant cDNAs of proteins in mammalian cells and evaluation of regulatory enzymes in controlling pathway flux(3) . Hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6-PF-2-K/Fru-2,6-P(2)ase) (^1)is a regulatory enzyme in the gluconeogenic/glycolytic pathway, which catalyzes both the synthesis and degradation of the signal molecule, Fru-2,6-P(2), an allosteric activator of 6-phosphofructo-1-kinase and an inhibitor of fructose-1,6-bisphosphatase(4, 5, 6) . The enzyme has been postulated to provide a switching mechanism between the glycolytic and gluconeogenic pathways in liver(7) . The kinase and bisphosphatase activities are reciprocally regulated by cAMP-dependent protein kinase-catalyzed phosphorylation(1) . Gene expression of the enzyme is subject to multihormonal regulation; insulin and glucocorticoids enhance and cAMP suppresses gene transcription(1) . Therefore, the level of Fru-2,6-P(2) and, ipso facto, glycolytic and gluconeogenic flux depend in a complex way on hormonal milieu.

A number of questions with regard to the bifunctional enzyme and metabolic pathway flux remain unanswered: 1) what is the relative importance of covalent modification and the concentration of bifunctional enzyme protein in controlling Fru-2,6-P(2) levels; 2) what are the relative roles of the kinase and bisphosphatase activities in determining the level of Fru-2,6-P(2); and 3) what is the role of Fru-2,6-P(2) in determining gluconeogenic pathway flux? It was the object of this study to address these questions by using recombinant adenovirus to overexpress wild-type 6-PF-2-K/Fru-2,6-P(2)ase and a double mutant (S32A/H258A) of the protein, which only possesses 6-PF-2-K activity and cannot be down-regulated by cAMP-dependent protein kinase-catalyzed phosphorylation. Mutation of Ser-32 to Ala prevents cAMP-dependent phosphorylation of the enzyme(8) , while mutation of His-258 to alanine abolishes bisphosphatase activity, since this residue is known to mediate catalysis via a phosphohistidine intermediate(9, 10) . Sincethey are capable of producing glucose from 3-carbon precursors(11, 12, 13, 14) , cultured rat hepatoma FAO cells were chosen to overexpress the enzyme forms. Thus, the switching mechanism between glycolysis and gluconeogenesis, hypothesized for the bifunctional enzyme and Fru-2,6-P(2), can be studied.


EXPERIMENTAL PROCEDURES

Materials

RPMI 1640, Dulbecco's modified Eagle's medium, and FBS were obtained from Life Technologies, Inc. Stat-60 reagent was from Tel-Test ``B'', Inc. (Friendswood, TX). Gene Screen membrane was obtained from DuPont NEN, and Immobilon PVDF from Millipore Corp. The BlueScript SK+ plasmid was purchased from Stratagene (San Diego, CA). All enzymes and chemicals were obtained from Sigma. Secondary antibody and color reagents were purchased from Boehringer-Mannheim.

Cell Culture

Monolayer cultures of rat FAO hepatoma-derived cells (14) were grown in RPMI 1640 medium (11 mM glucose) supplemented with 10% FBS. All experiments were carried out before the cells became confluent. The Ad-E1A-transformed human embryonic kidney cell line 293 (15) was cultured in Dulbecco's modified Eagle's medium containing 10% FBS.

Preparation of Recombinant Adenovirus

Adenoviral vectors were prepared using cDNAs coding for wild-type and mutant forms of rat liver 6-PF-2-K/Fru-2,6-P(2)ase, including a S32A mutant (8) and a H258A mutant(10) . Two HindIII restriction sites were engineered at the 5` and 3` ends of the cDNA by polymerase chain reaction: one 172 base pairs upstream of the ATG site and another 1511 base pairs downstream of the start codon (1.68 kb). The HindIII/HindIII fragment includes all of the coding sequence (1.41 kb)(16) , 0.172 kb of wild-type 5`-untranslated region, and 0.096 kb of wild-type 3`-untranslated region. Recombinant adenoviruses containing the cDNA encoding the wild-type or double mutant (S32A/H258A) 6-PF-2-K/Fru-2,6-P(2)ase were constructed using two plasmids, pACCMVpLpA (17) and pJM17(18) , by the strategy summarized in Fig. 1and as described previously(3, 19) . The resulting recombinant virus containing the wild-type 6-PF-2-K/Fru-2,6-P(2)ase enzyme is denoted Ad-PF2KWT, and the virus containing the double mutant 6-PF-2-K/Fru-2,6-P(2)ase is denoted Ad-PF2KMut. The presence of the 6-PF-2-K/Fru-2,6-P(2)ase cDNA insert in the recombinant virus was confirmed by restriction enzyme digestion and Southern blotting (data not shown). All recombinant adenoviruses were stored at a concentration of 1-4 times 10^8 plaque-forming units/ml in Dulbecco's modified Eagle's medium supplemented with 10% FBS.


Figure 1: Schematic representation of the strategy used for construction of Ad-PF2KWT. The pACCMVpLpA plasmid contains the transcription unit consisting of the cytomegalovirus early gene promoter/enhancer, the rat liver 6-PF-2-K/Fru-2,6-P(2)ase cDNA, and the SV40 polyadenylation genome. In the plasmid, the transcription unit is inserted in a partial deletion site (1.3/9.1 map units) within the adenovirus (Ad5) early region 1 (0/17 map units). The pJM17 plasmid contains the Ad5 cDNA (36 kb = 100 map units), in which the 4.3 kb plasmid pBRX encoding amoxicillin and tetracycline resistance was inserted at the Ad5 XbaI site. Homologous recombination between the two plasmids in the 293 cell generates replication-defective adenoviruses, since adenovirus early region 1 is replaced by the cloned chimeric gene. Three recombinant viruses were generated: AdWT, Ad-PF2KWT, and Ad-PF2KMut (see ``Experimental Procedures''). This scheme represents the construction of the Ad-PF2KWT.



Cell Treatment

FAO cells were transduced at a multiplicity of infection of 10 (10 plaque-forming units/cell) for 2 h with stocks of either a control recombinant adenovirus (AdWT) containing the cytomegalovirus promoter, pUC 18 polylinker, and a fragment of the SV40 genome or the recombinant adenoviruses Ad-PF2KWT or Ad-PF2KMut. Transduced cells were incubated for 48 h at 37 °C in 5% CO(2) and RPMI medium with 0.1% bovine serum albumin. No FBS was added in order to minimize cell division and to avoid a hormonal effect on gene expression and/or on the activities of overexpressed enzymes. In each experiment, 6-PF-2-K/Fru-2,6-P(2)ase mRNA and protein levels, activities, Fru-2,6-P(2), and production of glucose, lactate, and pyruvate were measured. The experiments were performed 48 h after the viral incubation and repeated 5-10 times. The efficiency of adenovirus-mediated gene transfer was approximately 70% as measured by immunocytochemistry and with a recombinant adenovirus containing the bacterial beta-galactosidase gene (data not shown). The survival of the FAO hepatoma cell line was unaffected by incubation of cells with the different adenovirus constructs since the dry mass of the attached cells in 55 cm^2 plates was the same after 48 h in treated or untreated cell plates (untreated, 6.5 ± 0.5 mg; AdWT, 6.7 ± 0.7 mg; Ad-PF2KWT, 6.8 ± 0.8 mg; Ad-PF2KMut, 6.8 ± 0.3 mg; n = 5 for each group).

RNA Extraction and Northern Blot Analysis

Total RNA was prepared from plated FAO cells by extraction with Stat-60 following the protocol of the manufacturer. RNA was denatured, electrophoresed, and transferred to a nylon membrane (Gene Screen) as described by Hod et al.(20) . A 1.4-kb EcoRI fragment of rat liver 6-PF-2-K/Fru-2,6-P(2)ase cDNA and a 2-kb PstI fragment of chicken brain beta-actin cDNA (21) were labeled with [alpha-P]dCTP by the random primer method(22) . Northern blots were hybridized with the labeled probe and washed as described previously(23) . Autoradiographs were scanned on a Bio-Rad imaging densitometer, model GS-670, and analyzed with the Bio-Rad Molecular Analyst software package. The beta-actin mRNA was used to normalize the overexpressed 6-PF-2-K/Fru-2,6-P(2)ase mRNA.

Ribonuclease Protection Assay

An RNA probe was designed to distinguish the wild-type from the mutant form (S32A/H258A) of rat liver 6-PF-2-K/Fru-2,6-P(2)ase mRNA. The 0.5-kb EcoRI fragment previously described (16) was cloned into the EcoRI restriction site of the plasmid BlueScript SK. The plasmid was linearized by digestion with BglII and was used to synthesize antisense RNA using its T3 RNA polymerase. The synthesized riboprobe was 297 bases long, 230 bases of which were complementary to the rat liver 6-PF-2-K/Fru-2,6-P(2)ase mRNA, including the DNA region mutated to code for an Ala instead of Ser at position 32. The wild-type 6-PF-2-K/Fru-2,6-P(2)ase mRNA would protect a 230-base fragment, and the mutant (S32A/H258A) would protect two fragments of 179 and 49 bases. Liver and skeletal muscle forms of mRNA were used as size standards. The ribonuclease protection assay was performed as described previously(24, 25) .

Enzyme Extractions and Western Blot Analysis

6-PF-2-K/Fru-2,6-P(2)ase protein was extracted in homogenizing buffer (20 mM TES, pH 7.8, 10 mM KCl, 1 mM dithiothreitol, 5 mM EDTA, 5 mM EGTA, 1.2 mM phenylmethanesulfonyl fluoride and 2.5 mg/liter leupeptin) and concentrated by precipitation with 65% saturated (NH(4))(2)SO(4). The precipitate was dissolved in 20 mM TES, pH 7.5, 100 mM KCl, 1 mM dithiothrietol, 0.1 mM EDTA, 0.5 mM phenylmethanesulfonyl fluoride, and 2.5 mg/liter leupeptin. Under these conditions, the in situ phosphorylation state of the enzyme is preserved(26) . For Western blot analysis, 100 µg of total protein was electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (10% acrylamide) and electrophoretically transferred overnight to a polyvinylidene difluoride membrane (Immobilon PVDF) as described by Colosia et al.(16) . Excess sites on the membrane were saturated with 3% bovine serum albumin in a PBS buffer, pH 7.4, containing 237 mM NaCl, 2.7 mM KCl, 5.4 mM Na(2)PO(4), 1.8 mM KH(2)PO(4). The membrane was incubated for 2 h at 37 °C with a 1:1000 dilution of polyclonal 6-PF-2-K/Fru-2,6-P(2)ase antibody (27) and then for 2 h at 37 °C with a 1:25,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG. The protein was visualized with color reagent. All washings were done in PBS buffer.

Assays of Kinase and Bisphosphatase Activities

The maximal velocity of 6-PF-2-K was assayed at 30 °C and pH 6.9 by measuring the rate of production of Fru-2,6-P(2) from 5 mM Fru-6-P and 5 mM ATP in the presence of 5 mM P(i). S(0.5) for Fru-6-P was determined for concentrations between 25 µM and 5 mM at pH 6.9. Fru-2,6-P(2) was assayed by its ability to activate pyrophosphate-dependent 6-phosphofructo-1-kinase from potato tubers(28) . Maximal velocity of Fru-2,6-P(2)ase was assayed by P(i) released from 5 µM [2-P]Fru-2,6-P(2) in the presence of 5 mM P(i) at 30 °C. The P(i) was separated from [2-P]Fru-2,6-P(2) by anion exchange chromatography (DEAE-Sephadex A25) and elution with triethylamine/HCO(3)(29) .

Fru-2,6-P(2)Extraction and Assay

Fru-2,6-P(2) was extracted at 100 °C in 0.1 M NaOH and measured using the 6-phosphofructo-1-kinase activation assay(28) .

Measurements of Gluconeogenesis and Glycolysis

Glucose, lactate, and pyruvate production was measured in 55-cm^2 plates of FAO cells that were incubated from 30 min to 3 h at 37 °C with atmospheric air, 5% CO(2) in 3 ml of Krebs bicarbonate buffer at pH 7.4 (120 mM NaCl, 4.8 mM KCl, 1.2 mM KH(2)PO(4), 1.2 mM MgSO(4), 24 mM NaHCO(3), 2.4 mM CaCl(2)) containing 20 mM dihydroxyacetone, 20 mM lactate plus pyruvate as a gluconeogenic substrate, or 30 mM glucose. A volume of 1.8 ml of incubation medium was taken and acidified with HClO(4) (5%, w/v) and then neutralized as described previously by Argaud et al.(30, 31) . At the end of the incubation, the cells were washed, scraped, and dried for 12 h at 180 °C for dry mass determination. Glucose, lactate, and pyruvate concentrations were measured spectrophotometrically using standard enzymatic methods (32) in neutralized protein-free extracts. Glucose, lactate, and pyruvate production are reported as nmol/plate produced in a 55-cm^2 plate (2 times 10^7 cells). All of the metabolic results are expressed as means ± S.E., and comparisons were made using Student's t test for unpaired samples.


RESULTS

Overexpression of the Wild-type and Mutated Form of Rat Hepatic 6-PF-2-K/Fru-2,6-P(2)ase

The levels of 6-PF-2-K/Fru-2,6-P(2)ase mRNA and protein in FAO cells were quantified 48 h after treatment of FAO cells with Ad-PF2KWT, Ad-PF2KMut, or wild-type adenovirus 5 (AdWT). As described previously(25) , FAO cells express low levels of the liver form of 6-PF-2-K/Fru-2,6-P(2)ase mRNA, and treatment with AdWT itself did not change the abundance of this mRNA (Fig. 2). When the FAO cells were treated with either Ad-PF2KWT or Ad-PF2KMut, 6-PF-2-K/Fru-2,6-P(2)ase mRNA increased about 150-fold (Fig. 2), whereas the beta-actin mRNA increased less than 20% (data not shown).


Figure 2: Northern blot analysis and quantification of overexpression of wild-type or mutated 6-PF-2-K/Fru-2,6-P(2)ase mRNA. Northern analysis of 20 µg of RNA extracted from treated FAO cells with different adenovirus constructs (AdWT, Ad-PF2KWT, Ad-PF2KMut), from untreated FAO, and from refed liver. A 1.4-kb EcoRI fragment of rat liver 6-PF-2-K/Fru-2,6-P(2)ase cDNA was used as a probe. The autoradiograph was obtained after a 1-h exposure with two intensifying screens. mRNA was quantified by scanning densitometry.



Overexpression of the wild-type and double mutant (S32A/H258A) 6-PF-2-K/Fru-2,6-P(2)ase mRNAs was verified by ribonuclease protection assay (Fig. 3). As expected, a 230-base complementary fragment was protected with rat liver RNA (lane L) and with RNA from FAO cells treated with Ad-PF2KWT (lane 2), while a 179-base fragment was observed with RNA from FAO cells transduced with Ad-PF2KMut (lane 3). The 297-base nucleotide riboprobe protects a fragment that includes part of exon I specific for the liver 6-PF-2-K/Fru 2,6-P(2) mRNA and part of exon I which is shared by both the liver and skeletal muscle forms of 6-PF-2K/Fru-2,6-P(2)ase mRNA(25) . Moreover, the 5` end of exon II corresponds to the sequence encoding the S32A mutation site. Hence, the fragment protected by the rat skeletal muscle mRNA was the same size as the fragment protected by the mutant form (S32A/H258A) of 6-PF-2-K/Fru-2,6-P(2)ase mRNA, i.e. 179 bases (Fig. 3, lanes M and 3). These results provide definitive evidence that the wild-type and mutant bifunctional enzyme mRNAs were overexpressed.


Figure 3: RNase protection analysis. The RNase protection assay was designed as described under ``Experimental Procedures,'' and 20 µg of RNA obtained from different sources were protected with the 297-base probe. Lane Pr contains undigested RNA probe; the other lanes contain protected fragments after hybridation of the probe with RNA from different sources and digestion with RNase. FAO cells treated with either AdWT (lane 1), Ad-PF2KWT (lane 2), or Ad-PF2KMut (lane 3), rat liver (lane L), and rat skeletal muscle (40 µg) (lane M) are shown. MWSt, molecular weight standard.



Immunofluorescence studies were performed on monolayer cultures of FAO cells by exposing these cells to an anti-bifunctional enzyme antibody (27) . A high level of bifunctional protein was detected in cells treated with Ad-PF2KWT or Ad-PF2KMut, whereas the protein was undetectable in control FAO cells incubated or not incubated with AdWT (data not shown). Both forms of overexpressed protein were homogeneously detected in the cytosol of FAO cells, with no apparent localization to any subcellular structure.

Western blot analysis (Fig. 4) confirmed that the wild-type (lanes 3 and 6) and the mutated form (lane 4) of overexpressed 6-PF-2-K/Fru-2,6-P(2)ase were the same size as the wild-type rat liver 6-PF-2-K/Fru-2,6-P(2)ase (55 kDa) (lane 7). FAO cells incubated in the presence of 30 mM glucose contained a small quantity of the liver form of 6-PF-2-K/Fru-2,6-P(2)ase (lane 5), whereas no measureable signal was obtained at the 11 mM glucose in control cells (lane 1) or in cells treated with AdWT (lane 2). 6-PF-2-K/Fru-2,6-P(2)ase protein in FAO cells incubated with either Ad-PF2KWT (lanes 3 and 6) or Ad-PF2KMut (lane 4) was 40-fold greater than in the control (lane 5) and was not dependent on glucose concentration.


Figure 4: Western blot analysis of overexpressed 6-PF-2-K/Fru-2,6-P(2)ase protein. Proteins were extracted and treated with 65% (NH(4))(2)SO(4) as described under ``Experimental Procedures'' from untreated FAO cells (lane 1) or from transduced FAO cells with different adenovirus constructs: AdWT (lanes 2 and 5), Ad-PF2KWT (lanes 3 and 6), and Ad-PF2KMut (lane 4). The glucose concentration was different in incubation medium during the 48 h after infection (30 instead of 11 mM for lanes 5 and 6). 100 µg of protein/lane were electrophoresed in 10% SDS-polyacrylamide gel and electrophoretically transferred to a PVDF membrane as described under ``Experimental Procedures.'' The 6-PF-2-K/Fru-2,6-P(2)ase protein was detected with a polyclonal antibody obtained from a rat liver 6-PF-2-K/Fru-2,6-P(2)ase protein extract. 0.05 µg of rat liver 6-PF-2-K/Fru-2,6-P(2)ase protein was used as positive control (lane 7). This protein was extracted and purified from bacteria engineered for expression rat liver 6-PF-2-K/Fru-2,6-P(2)ase protein. Protein was quantified by scanning densitometry. MWSt, molecular weight standard.



Since maximal velocity values for the kinase and bisphosphatase reflect the amount of enzyme(16) , 6-PF-2-K and Fru-2,6-P(2)ase activities were assayed in order to determine whether activity correlated with the amount of protein. As expected, when the wild-type 6-PF-2-K/Fru-2,6-P(2)ase was overexpressed, both activities increased, 22-fold for the kinase and 29-fold for the bisphosphatase (Table 1). When the double mutant was overexpressed, kinase activity increased 28-fold, whereas bisphosphatase activity increased 6-fold (Table 1), even though the bisphosphatase domain was presumably inactivated. The maximal velocities of both activities were measured under the same conditions of pH, temperature, and P(i) concentration. An increase in the kinase:bisphosphatase maximal activity ratio of 4-fold was obtained when the mutated form (S32A/H258A) was overexpressed (Table 1). In contrast, a significant decrease (1.7 ± 0.2 versus 3.0 ± 0.7; p < 0.05) in this ratio was obtained when the wild-type enzyme was overexpressed.



Consequences of Overexpression of the Wild-type and Mutated Form of 6-PF-2-K/Fru-2,6-P(2)ases on Fru-2,6-P(2)ase levels

Overexpression of the wild-type enzyme resulted in a 70% decrease in Fru-2,6-P(2) levels relative to the control level (Table 1). In contrast, overexpression of the mutant form resulted in a 3-4-fold increase in the level of Fru-2,6-P(2). Since the wild-type enzyme is subject to cAMP-dependent phosphorylation with concomitant inhibition of the kinase and activation of the bisphosphatase, it is possible that phosphorylation of the enzyme in FAO cells accounts for decrease in Fru-2,6-P(2) levels.

Effect of 8-CPT-cAMP on FAO Cell 6-Phosphofructo-2-kinase Activity

In order to ascertain whether the overexpressed bifunctional enzyme in FAO cells was subject to regulation by cAMP-dependent protein kinase-catalyzed phosphorylation, 8-CTP-cAMP (100 µM) was added to cells 48 h after treatment with either Ad-PF2KWT or Ad-PF2KMut. As observed with endogenous 6-PF-2-K/Fru-2,6-P(2)ase in H4IIE cells (33) , a 20-min exposure to the cAMP analog increased by 1.5-fold the S(0.5) for Fru-6-P of the wild-type overexpressed 6-PF-2-K, from 320 µM to 466 µM. As expected, the S(0.5) was unchanged by incubation with the cAMP analog when the double mutant form was overexpressed (253 µMversus 203 µM with cAMP). The higher S(0.5) for Fru-6-P (320 µMversus 253 µM) of the wild-type enzyme compared with the double mutant in cells incubated without 8-CPT-cAMP is consistent with phosphorylation of the overexpressed wild-type enzyme.

Gluconeogenesis and Glycolysis in FAO Cells

FAO cells contain all of the gluconeogenic enzymes required for growth and survival in the absence of glucose(11, 12) , and they can produce glucose from gluconeogenic precursors(13) . However, quantitative studies on glucose metabolism in these cells have not been reported. As shown in Fig. 5, FAO cells produced glucose from lactate plus pyruvate (10:1) (2.5 nmol/min/plate) or from dihydroxyacetone (1.5 nmol/min/plate). (^2)In contrast to isolated hepatocytes(30, 31) , the rate of glucose production was higher with lactate plus pyruvate than with dihydroxyacetone during the last 2 h, and the addition of 2 mM oleate did not stimulate glucose production from lactate plus pyruvate (data not shown). Since most cancer cell lines have high rates of glycolysis(34, 35) , FAO cells were incubated with 30 mM glucose, and lactate plus pyruvate production was measured. In the first 30 min, the rate of lactate plus pyruvate production, after subtraction of endogenous lactate plus pyruvate production,^2 was 8.3 nmol/min/plate, but thereafter, the rate declined to nearly 0. These results demonstrate that FAO cells synthesize glucose from 3-carbon precursors and that glycolysis from glucose is very low.


Figure 5: Glucose production in FAO cells. 55-cm^2 plates of FAO cells were incubated for 1, 2, or 3 h with 3 ml of Krebs-bicarbonate, pH 7.4, containing 2% bovine serum albumin and 20 mM lactate plus pyruvate (10:1) (box) or 20 mM dihydroxyacetone (). Glucose were measured in the incubation medium of each plate as described under ``Experimental Procedures.'' Results are the mean ± S.E. (n = 4) for dihydroxyacetone and n = 1 for lactate plus pyruvate.



Effect of Overexpression of Wild-type and Mutated Bifunctional Enzyme on Dihydroxyacetone Metabolism

Since FAO cells did not produce a large amount of lactate plus pyruvate from glucose, dihydroxyacetone was used to study the effect of overexpression of the bifunctional enzyme forms and the associated changes in Fru-2,6-P(2) on glucose and lactate plus pyruvate production. Dihydroxyacetone is phosphorylated by glycerokinase or D-triokinase to dihydoxyacetone phosphate(36) , which then can be converted either to glucose or to lactate plus pyruvate. Addition of 20 mM dihydroxyacetone increased Fru-2,6-P(2) levels by 5-fold in FAO cells during the 3-h incubation. However, as was the case with FAO cells incubated in RPMI medium containing 11 mM glucose, overexpression of the wild-type enzyme decreased and overexpression of the double mutant increased Fru-2,6-P(2) levels compared with that in treated or untreated control cells with AdWT (data not shown). Incubation of FAO cells with AdWT did not affect glucose production from 20 mM dihydroxyacetone during the 3-h incubation (322 ± 14 nmol/plate versus 348 ± 13; n = 4, n.s.). Production of lactate plus pyruvate was also unaffected (1529 ± 105 versus 1823 ± 120 nmol/plate; n = 4, n.s.) (data not shown).

Overexpression of the mutant bifunctional enzyme had a dramatic inhibitory effect on the rate of glucose production from dihydroxyacetone, with almost zero glucose production during the third hour (0.1 nmol/min/plate for Ad-PF2KMut versus 1 nmol/min/plate for AdWT) (Fig. 6A). The effect was time-dependent; there was 10% inhibition after the first hour, 24% after the second hour, and 92% after the third hour (Fig. 6A). There was at the same time a stimulation of lactate plus pyruvate production that was also time-dependent; there was a 6% increase after the first hour, 19% after the second hour, and 220% after the third hour (Fig. 6B). As shown in Table 2, only 40% of the additional lactate plus pyruvate production could be accounted for by the inhibition of glucose production (192 versus 493 nmol).


Figure 6: Effect of overexpression of wild-type or mutated 6-PF-2-K/Fru-2,6-P(2) on glucose and lactate plus pyruvate production in FAO cells. 55-cm^2 plates of FAO cells treated with different adenovirus constructs; AdWT (box), Ad-PF2KWT (), and Ad-PF2KMut () were incubated 1, 2, or 3 h with 3 ml of Krebs-bicarbonate, pH 7.4, containing 2% bovine serum albumin and 20 mM dihydroxyacetone. Glucose (A) and lactate plus pyruvate (B) productions were measured in the incubation medium of each plate as described under ``Experimental Procedures.'' 2Glc + Lac + Pyr is the sum of glucose and lactate plus pyruvate production in 3-carbon equivalent (C). Results are the mean ± S.E., n = 4.





In contrast, overexpression of the wild-type form stimulated the rate of glucose production from dihydroxyacetone; there was a 25% increase after the first hour and a 50% increase after both the second and third hours (Fig. 6A). Lactate plus pyruvate production was simultaneously decreased (Fig. 6B). The stimulation of glucose production was almost completely accounted for by the inhibition of lactate plus pyruvate production (Table 2). After 3 h, 228 nmol more of 3-carbon precursors were used to synthesize glucose, whereas 295 nmol less of 3-carbon precursors were used to synthesize lactate plus pyruvate in Ad-PF2KWT-infected cells than in cells infected with the vector. The sum of 3-carbon equivalents of glucose and lactate plus pyruvate production was not significantly different during the incubation time for Ad-PF2KWT- versus AdWT-treated cells (Fig. 6C, 2106 ± 171 nmol/plate versus 2173 ± 118 nmol/plate, n = 4; n.s.).

The rate of glucose production was higher during the first hour than in the last 2 h in both treated and untreated cells, but the rate of dihydroxyacetone metabolism to glucose or lactate plus pyruvate was constant for the first 2 h (Fig. 6C). The lack of linearity of glucose production reflects a change in the balance between glucose and lactate plus pyruvate production from dihydroxyacetone after the first hour. This balance was also affected by the overexpression of both forms of the enzyme. During the last 2 h, in AdWT-treated or untreated FAO cells, about 30% of the 3-carbon precursors were used for glucose synthesis and about 70% for lactate plus pyruvate formation. With overexpression of the double mutant and the associated increase in Fru-2,6-P(2) level, only about 20% of dihydroxyacetone was used for glucose formation and about 80% for lactate plus pyruvate formation, whereas with overexpression of the wild-type enzyme and the decrease in Fru-2,6-P(2) level, about 40% of dihydroxyacetone was converted to glucose and about 60% to lactate plus pyruvate.


DISCUSSION

A relationship between Fru-2,6-P(2) levels and hepatic gluconeogenesis and glycolysis has been established by studies on nutritional status and metabolic disease states, such as diabetes(1, 37) . The role of Fru-2,6-P(2) in regulating metabolic fluxes has also been studied by correlating pathway flux with acute changes in Fru-2,6-P(2) level brought about by hormones like glucagon, insulin, and vasopressin (37) . However, changes in nutritional status and/or hormones involves modulation of other regulatory enzymes as well(38, 39, 40) , and this has made it difficult to determine the importance of any individual step. The ability to overexpress wild-type 6-PF-2-K/Fru-2,6-P(2)ase or a double mutant that has no bisphosphatase activity allowed us to analyze the relative role of the kinase and bisphosphatase in regulating Fru-2,6-P(2) levels and metabolic flux through the gluconeogenic/glycolytic pathway. Overexpression of wild-type 6-PF-2-K/Fru-2,6-P(2)ase decreased Fru-2,6-P(2) levels and increased glucose production from dihydroxyacetone while inhibiting lactate plus pyruvate production. In contrast, overexpression of the double mutant increased Fru-2,6-P(2) levels and inhibited glucose production from dihydroxyacetone, while stimulating lactate plus pyruvate production. These results support the importance of Fru-2,6-P(2) as a regulator of the gluconeogenic/glycolytic pathway in FAO cells.

There have been only a limited number of reports of overexpression of enzymes of mammalian glucose metabolism with concomitant analysis of the consequences on pathway flux(19, 41, 42, 43, 44) . (^3)In several instances there was not a perfect quantitative correlation between overexpression of an enzyme and the predicted metabolic consequences of that overexpression. For example, a 10-100-fold overexpression of hexokinase I in a pancreatic beta-cell line (MIN 6) (41) or in isolated islets of Langerhans (42) enhanced glucose utilization or insulin secretion by only 2-fold. Overexpression of glycogen phosphorylase by 46-fold in primary hepatocytes did not change glycogen content in the basal state, although preferential activation of glycogenolysis was evident upon treatment with pharmacologic agents(19) . Overexpression of glucokinase in islets had no effect on glucose utilization or insulin secretion.^3 These results suggest that other steps in a pathway may become rate-limiting when one enzymatic step is enhanced by overproduction of the protein and/or that other as yet unrecognized regulatory mechanisms may be revealed by overexpression. On the other hand, overexpression of phosphoenolpyruvate carboxykinase in H4IIE-C3 cells (43) or of glucokinase in the same cell line or in FTO-2B cells (44) was quantitatively correlated with enhanced pathway fluxes, gluconeogenesis, and glycolysis, respectively.

The changes in Fru-2,6-P(2) levels were better correlated with the change in the kinase:bisphosphatase maximal activity ratio than with the kinase maximal activity, which was enhanced 22-28-fold in the case of overexpression of the wild-type and double mutant enzymes. However, there were a number of unexpected findings: 1) mRNA abundances of the wild-type enzyme and its double mutant were increased to a greater extent than the protein level. This discrepancy may be due to a higher rate of expression of the mRNA relative to the FAO cells' ability to translate and/or process the mRNA. The apparent discrepancy between massive overexpression of the enzyme and relatively modest effects on Fru-2,6-P(2) concentration may reflect the heterogeneity of the FAO cells since the efficiency of gene transfer was 70%. 2) Overexpression of the wild-type enzyme resulted in a decrease in Fru-2,6-P(2) level. 3) Overexpression of the double mutant resulted in a nearly 6-fold increase in bisphosphatase, even though this enzyme form is devoid of significant bisphosphatase activity(10) .

The paradoxical drop in Fru-2,6-P(2) argues for covalent modification of the overexpressed wild-type enzyme in FAO cells. Cyclic AMP-dependent protein kinase-catalyzed phosphorylation increases the kinase S(0.5) for Fru-6-P and has no effect on the kinase maximal velocity but enhances the bisphosphatase maximal velocity 2-3-fold(1) . Phosphorylation of the overexpressed wild-type enzyme is supported by both the higher S(0.5) for Fru-6-P of the 6-PF-2-K, compared with the double mutant, and the decrease in the kinase:bisphosphatase maximal activity ratio compared with the ratio for the enzyme in untreated or vector-treated cells. (^4)The question remains as to why the overexpressed enzyme is phosphorylated to a greater extent than the endogenous enzyme. In untreated FAO cells, the enzyme would be predicted to have a low phosphate content, since the concentration of 6-PF-2-K/Fru-2,6-P(2)ase was estimated to be less than 1 µM by Western blot analysis (data not shown), which is far below its K(m) (10 µM) for phosphorylation by cAMP-dependent protein kinase(45) . An increase in bifunctional enzyme concentration to about 40 µM after overexpression would be predicted to enhance its extent of phosphorylation in FAO cells. However, the possibility that an unrecognized covalent modification of the enzyme inhibits maximal kinase activity cannot be ruled out. For example, it has recently been demonstrated that in vitro ADP-ribosylation of the liver enzyme inactivates the kinase, but has no effect on the bisphosphatase(46) .

Overexpression of the double mutant increased the kinase:bisphosphatase ratio and increased Fru-2,6-P(2) levels, as expected. However, the 6-fold increase in bisphosphatase activity was surprising, since this mutant lacks the histidine residue needed to form the phosphoenzyme intermediate that mediates Fru-2,6-P(2) hydrolysis(9, 10) . Despite the inability to form phosphoenzyme intermediate, the H258A mutant retains a very low residual activity, (^5)and overexpression of the protein by 40-fold may account in part for the increased bisphosphatase activity. Increased phosphorylation of the overexpressed enzyme is unlikely to have contributed to the increased bisphosphatase activity, since the phosphorylation site (Ser-32) also was mutated to Ala. It has been reported that Ser-33 can undergo phosphorylation in vitro but at a very low rate and with negligible effect on the bisphosphatase(8) . It also cannot be ruled out that the endogenous enzyme underwent phosphorylation as a result of the large increase in total bifunctional enzyme protein, resulting in enhanced bisphosphatase activity. However, this phosphorylation would not fully explain the 6-fold increase in total bisphosphatase activity. This change probably involves both residual activity of the overexpressed protein and phosphorylation of the endogenous enzyme.

The results reported here also support previous work with H4IIE cells, which demonstrated that regulation of the activities of the bifunctional enzyme and Fru-2,6-P(2) levels by covalent modification is more important than changes in amount of this two-domain protein(33) . For example, dexamethasone, which did not affect phosphorylation state, increased bifunctional enzyme mRNA (11-fold) and protein (3-fold) but had only a small effect on Fru-2,6-P(2) content. In contrast, insulin, which increased the kinase:bisphosphatase activity ratio by causing dephosphorylation of the enzyme, increased Fru-2,6-P(2) content by 15-fold. Although the phosphorylation state of the enzyme is probably the most important determinant of net synthesis or degradation of Fru-2,6-P(2), it is likely that the amount of the enzyme is important in some situations, i.e. lipogenic conditions, where elevated Fru-2,6-P(2) levels have been correlated with increased enzyme amount(16) . In addition, insulin and dexamethasone had highly synergistic effects on Fru-2,6-P(2) in H4IIE cells by altering both the phosphorylation state and the amount of protein(33) .

As shown previously, FAO cells are capable of synthesizing glucose from various 3-carbon precursors(13) . Rates of glucose synthesis from lactate/pyruvate (10:1) or dihydroxyacetone are between 5 and 15% (0.3-0.7 µmol/min/dry mass) that of isolated hepatocytes(30, 31) and perfused liver(47) , depending on the substrate and growth medium. The lower rate of glucose production may also be due to differences in incubation conditions and/or to different rate-limiting steps in hepatocytes versus hepatoma cells, since the latter contain lower fructose-1,6-bisphosphatase activity and higher phosphoenolpyruvate carboxykinase activity(11, 12) . However, the rate of glucose synthesis in FAO cells was high enough to study the role of Fru-2,6-P(2) in regulation of glycolytic and gluconeogenic flux, particularly with the use of dihydroxyacetone.

Tumor cells are usually thought to have high rates of glycolysis(34, 35) . However, like other rat hepatoma cell lines such as FT0-2B and H4IIE(44) , and in contrast to isolated hepatocytes, FAO cells exhibit very low rates of glycolysis from glucose but a high lactate plus pyruvate production from dihydroxyacetone. The lack of expression of the glucokinase gene in FAO cells (data not shown) and in other rat hepatoma cell lines such as FT0-2B and H4IIE (44) compared with isolated hepatocytes (7) probably accounts for the low glycolytic rate from glucose and the substrate effect (dihydroxyacetone versus glucose) on this rate.

The results of this study point to the utility of FAO cells as a model system for glycolytic/gluconeogenic pathway engineering. Adenoviral and/or retroviral constructs containing the coding region for glucokinase can be used to enhance glucose utilization in these cells and test the role of this and other enzymes in controlling glycolytic flux, substrate cycling, and Fru-2,6-P(2) levels. Such work is in progress.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants DK-38354 (to S. J. P.) and DK-46492 (to C. B. N.), and ALFEDIAM (France), Foreign Office of French Minister (Lavoisier program), Philippe Foundation (to D. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 612-625-6100; Fax: 612-625-2163.

Deceased August 3, 1995.

(^1)
6-PF-2-K/Fru-2,6-P(2)ase, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase or bifunctional enzyme; Fru-2,6-P(2), fructose 2,6-bisphosphate; Fru-6-P, fructose 6-phosphate; FBS, fetal bovine serum; TES, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid; n.s., not significant; 8-CPT-cAMP, sodium cacodylate and 8-(4-chlorophylthio)adenosine 3`:5` cyclic AMP; kb, kilobase(s).

(^2)
Endogenous glucose and lactate plus pyruvate production in the absence of added substrate were subtracted from rates in the presence of substrate (dihydroxyacetone, lactate plus pyruvate (10:1) and glucose).

(^3)
T. C. Becker, R. J. Noel, R. M. Lynch, J. H. Johnson, J. Takeda, G. I. Bell, and C. B. Newgard, submitted for publication.

(^4)
Despite the apparent partial phosphorylation of the overexpressed wild-type enzyme, Fru-2,6-P(2) levels would have been expected to rise, since the kinase:bisphosphatase maximal activity ratio was >1 (Table 1). However, it is possible that this ratio does not reflect the cellular situation. The Fru-2,6-P(2) concentration in livers from fed animals is 10-20 µM and 3 µM in FAO cells, whereas the K from Fru-2,6-P(2) of the bisphosphatase is 2-5 nM(29) . In contrast, the concentration of Fru-6-P is 50-200 µM, and the S(0.5) of the kinase has been reported to be 40-600 µM(8, 33) , with a value of about 200 µM for 6-PF-2-K of the overexpressed wild-type enzyme in FAO cells. Thus, the kinase operates at submaximal velocity, whereas the bisphosphatase operates at maximal velocity in intact cells. This suggests that the true kinase:bisphosphatase ratio in vivo is closer to 1. Furthermore, there are low molecular effectors (e.g. P(i) and alpha-glycerol phosphate) that can influence both activities and may play a role in the cell in affecting kinase/bisphosphatase activities.

(^5)
D. A. Okar and S. J. Pilkis, unpublished results.


ACKNOWLEDGEMENTS

We thank Nancy Browne for skillful typing of the manuscript and Ulf Arvidsson (Department of Cell Biology and Neuroanatomy, University of Minnesota) for help with the immunofluorescence studies. We also thank Dr. Tom Claus (Bayer, Pharmaceutical Division) for constructive criticism during preparation of the manuscript.


REFERENCES

  1. Pilkis, S. J., Claus, T. H., Kurland, I. J., and Lange, A. J. (1995) Annu. Rev. Biochem., (1995) 64, 799-835
  2. Pilkis, S. J., and Granner, D. K. (1992) Annu. Rev. Physiol. 54,885-909 [CrossRef][Medline] [Order article via Infotrieve]
  3. Becker, T. C., Noel, R. J., Coats, W. S., Gómez-Foix, A. M., Alam, T., Gerard, R. D., and Newgard, C. B. (1994) Methods Cell Biol. 43,161-189 [Medline] [Order article via Infotrieve]
  4. Pilkis, S. J., El-Maghrabi, M. R., Pilkis, J., Claus, T. H., and Cumming, D. A. (1981) J. Biol. Chem. 256,3171-3174 [Abstract/Free Full Text]
  5. Pilkis, S. J., El-Maghrabi, M. R., Pilkis, J., and Claus, T. (1981) J. Biol. Chem. 256,3619-3622 [Abstract/Free Full Text]
  6. Van Schaftingen, E., and Hers, H. G. (1981) Proc. Natl. Acad. Sci. U. S. A. 78,2861-2863 [Abstract]
  7. Pilkis, S. J., El-Maghrabi, M. R., and Claus, T. H. (1988) Annu. Rev. Biochem. 57,755-783 [CrossRef][Medline] [Order article via Infotrieve]
  8. Kurland, I. J., El-Maghrabi, M. R., Correia, J. J., and Pilkis, S. J. (1992) J. Biol. Chem. 267,4416-4423 [Abstract/Free Full Text]
  9. Pilkis, S. J., Lively, M. O., and El-Maghrabi, M. R. (1987) J. Biol. Chem. 262,12672-12675 [Abstract/Free Full Text]
  10. Tauler, A., Lin, K., and Pilkis, S. J. (1990) J. Biol. Chem. 265,15617-15622 [Abstract/Free Full Text]
  11. Bertolotti, R. (1977) Somatic Cell Genet. 3,365-380 [Medline] [Order article via Infotrieve]
  12. Deschatrette, J., Moore, E. E., Dubois, M., Cassio, D., and Weiss, M. C. (1979) Somatic Cell Genet. 5,697-718 [Medline] [Order article via Infotrieve]
  13. Kahn, C. R., Lauris, V., Koch, S., Crettaz, M., and Granner, D. K. (1989) Mol. Endocrinol. 3,840-845 [Abstract]
  14. Deschatrette, J., and Weiss, M. C. (1974) Biochimie (Paris) 56,1603-1611 [Medline] [Order article via Infotrieve]
  15. Graham, F. L., Simley, J., Russel, W. C., and Nairn, R. (1977) J. Gen. Virol. 36,59-72 [Abstract]
  16. Colosia, A. D., Marker, A. J., Lange, A. J., El-Maghrabi, M. R., Granner, D. K., Tauler, A., Pilkis, J., and Pilkis, S. J. (1988) J. Biol. Chem. 263,18669-18677 [Abstract/Free Full Text]
  17. Gluzman, Y., Reichl, H., and Solnick, D. (1982) Eucaryotic Viral Vectors (Gluzman, Y. ed.) pp 187-192, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  18. McGrory, W. J., Bautista, D. S., and Graham, F. L. (1988) Virology 163,614-617 [Medline] [Order article via Infotrieve]
  19. Gómez-Foix, A. M., Coats, W. S., Baqué, S., Alam, T., Gerard, R. D., and Newgard, C. B. (1992) J. Biol. Chem. 267,25129-25134 [Abstract/Free Full Text]
  20. Hod, Y., Morris, S. M., and Hanson, R. W. (1984) J. Biol. Chem. 259,15603-15608 [Abstract/Free Full Text]
  21. Cleveland, D. W., Lopala, M. A., MacDonald, R. J., Cowan, N. J., Rutter, W. J., and Kirschner, M. W. (1980) Cell 20,85-105 [Medline] [Order article via Infotrieve]
  22. Feinberg, A. P., and Vogelstein, B. (1984) Anal. Biochem. 137,266-267 [Medline] [Order article via Infotrieve]
  23. Lange, A. J., Argaud, D., El-Maghrabi, M. R., Pan, W., Maitra, S. R., and Pilkis, S. J. (1994) Biochem. Biophys. Res. Commun. 201,302-309 [CrossRef][Medline] [Order article via Infotrieve]
  24. Hod, Y. (1992) BioTechniques 13,852-853 [Medline] [Order article via Infotrieve]
  25. Espinet, C., Vargas, A. M., El-Maghrabi, M. R., Lange, A. J., and Pilkis, S. J. (1993) Biochem. J. 293,173-179 [Medline] [Order article via Infotrieve]
  26. Claus, T. H., Nyfeler, F., Muenkel, H. A., Burns, M. G., Pate, T., and Pilkis, S. J. (1984) Biochem. Biophys. Res. Commun. 125,655-661 [Medline] [Order article via Infotrieve]
  27. El-Maghrabi, M. R., Correia, J. J., Heil, P. J., Pate, T., Cobb, C. E., and Pilkis, S. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83,5005-5009 [Abstract]
  28. Van Schaftingen, E., Lederer, B., Bartrons, R., and Hers, H. G. (1982) Eur. J. Biochem. 129,191-195 [Abstract]
  29. El-Maghrabi, M. R., Claus, T. H., Pilkis, J., Fox, E., and Pilkis, S. J. (1982) J. Biol. Chem. 257,7603-7607 [Abstract/Free Full Text]
  30. Argaud, D., Halimi, S., Catelloni, F., and Leverve, X. M. (1991) Biochem. J. 280,663-669 [Medline] [Order article via Infotrieve]
  31. Argaud, D., Roth, H., Wiernsperger, N., and Leverve, X. M. (1993) Eur. J. Biochem. 213,1341-1348 [Abstract]
  32. Bergmeyer, H. U. (ed) (1974) Methods of Enzymatic Analysis , Vol. 3, pp. 1125-1624, 2nd Ed., Verlag Chemie, Academic Press, Inc., London
  33. Vargas, A. M., Sola, M. M., Lange, A. J., Poveda, G., and Pilkis, S. J. (1994) Diabetes 43,792-799 [Abstract]
  34. Weinhouse, S. (1972) Cancer Res. 32,2007-2016 [Medline] [Order article via Infotrieve]
  35. Schamhart, D. H. J., van de Poll, K. W., and van Wijk, R. (1979) Cancer Res. 39,1051-1055 [Abstract]
  36. Veneziale, C. M. (1976) Gluconeogenesis: Its Regulation in Mammalian Species (Hanson, R. W., and Mehlman, M. A., eds) pp. 463-480, John Wiley & Sons, Inc., New York
  37. Van Schaftingen, E. (1990) Fructose-2,6-bisphosphate (Pilkis, S., ed) pp. 65-85, CRC Press, Inc., Boca Raton, FL
  38. Halestrap, A. P. (1986) Hormonal Control of Gluconeogenesis (Kraus-Friedmann, N., ed) pp. 31-48, CRC Press, Inc., Boca Raton, FL
  39. Riou, J. P., Claus, T. H., and Pilkis, S. J. (1978) J. Biol. Chem. 253,656-669 [Abstract]
  40. Probst, I., and Unthan-Fechner, K. (1985) Eur. J. Biochem. 153,347-353 [Abstract]
  41. Ishihara, H., Asano, T., Tsukuda, K., Katagiri, H., Inukai, K., Anai, M., Kikuchi, M., Yazaki, Y., Miyazaki, J., and Oka, Y. (1994) J. Biol. Chem. 269,3081-3087 [Abstract/Free Full Text]
  42. Becker, T. C., BeltrandelRio, H., Noel, R. J., Johnson, J. H., and Newgard, C. B. (1994) J. Biol. Chem. 269,21234-21238 [Abstract/Free Full Text]
  43. Rosella, G., Zajac, J. D., Kaczmarczyk, S. J., Andrikopoulos, S., and Proietto, J. (1993) Mol. Endocrinol. 7,1456-1462 [Abstract]
  44. Valera, A. and Bosch, F. (1994) Eur. J. Biochem. 222,533-539 [Abstract]
  45. Murray, K. J., El-Maghrabi, M. R., Kountz, P. D., Lukas, T. J., Soderling, T. R., and Pilkis, S. J. (1984) J. Biol. Chem. 259,7673-7681 [Abstract/Free Full Text]
  46. Rosa, J. L., Perez, X., Ventura, F., Tauler, A., Gil, J., and Shimoyama, M. (1995) Biochem. J. , in press
  47. Exton, J. H., and Park, C. R. (1967) J. Biol. Chem. 242,2622-2636 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.